The drug, aducanumab, made by Biogen, would be the first new Alzheimer’s treatment in nearly two decades. But the advisory panel said there was not enough evidence of its effectiveness in slowing cognitive decline.
The post 2024 NIH, National Institute on Aging Director’s Regional Meeting appeared first on Arizona Alzheimer's Consortium.
Two-part trial to build on landmark Colombian prevention study of people at near-certain genetic risk for early-onset Alzheimer’s disease PHOENIX (Thursday, Nov. 14) – A new Alzheimer’s prevention study has received a $74.5 million five-year grant from the National...
APPLICATION RECEIPT DATE: Recommended: Pre-proposal Deadline: November 1, 2024 (Friday) Full Application Deadline: December 11, 2024 Anticipated Analysis Start Date: February 3, 2025 (Wednesday) PURPOSE: The Arizona Alzheimer’s Consortium (AAC) invites applications...
Hay alrededor de 10 variaciones de enfermedades de demencia y la más común es el Alzheimer. Haga clic aquí para leer la historia completa. | Click Here to Read the Full Story The post Los hispanos son 50% más propensos a contraer una enfermedad de demencia, según...
Living alone is a lesser-known risk factor for Alzheimer’s and other types of cognitive decline. With an estimated 14 million Americans aging solo — by choice or circumstance — Arizona State University has a plan to help and new funding to support it. This summer,...